PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.92%
Negative revenue growth while MCHP stands at 2.86%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-2.87%
Negative gross profit growth while MCHP is at 3.27%. Joel Greenblatt would examine cost competitiveness or demand decline.
-1.68%
Negative EBIT growth while MCHP is at 4.67%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-1.68%
Negative operating income growth while MCHP is at 4.67%. Joel Greenblatt would press for urgent turnaround measures.
-2.71%
Negative net income growth while MCHP stands at 75.31%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.18%
Share reduction while MCHP is at 1.11%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-3.45%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
25.02%
Dividend growth above 1.5x MCHP's 5.17%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-7.05%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-9.93%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
66.42%
10Y revenue/share CAGR under 50% of MCHP's 140.74%. Michael Burry would suspect a lasting competitive disadvantage.
96.86%
5Y revenue/share CAGR above 1.5x MCHP's 59.13%. David Dodd would look for consistent product or market expansions fueling outperformance.
41.72%
3Y revenue/share CAGR above 1.5x MCHP's 27.74%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
241.13%
10Y OCF/share CAGR above 1.5x MCHP's 124.34%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
127.23%
Positive OCF/share growth while MCHP is negative. John Neff might see a comparative advantage in operational cash viability.
37.02%
Positive 3Y OCF/share CAGR while MCHP is negative. John Neff might see a big short-term edge in operational efficiency.
401.02%
Net income/share CAGR at 50-75% of MCHP's 572.20%. Martin Whitman might question if the firm’s product or cost base lags behind.
252.29%
5Y net income/share CAGR at 50-75% of MCHP's 345.20%. Martin Whitman might see a shortfall in operational efficiency or brand power.
93.61%
3Y net income/share CAGR 50-75% of MCHP's 158.35%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
91.65%
Below 50% of MCHP's 452.02%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
10.40%
Below 50% of MCHP's 70.93%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
-4.05%
Negative 3Y equity/share growth while MCHP is at 43.84%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
361.20%
Dividend/share CAGR of 361.20% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
355.42%
Dividend/share CAGR of 355.42% while MCHP is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
294.10%
Below 50% of MCHP's 646.21%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-13.89%
Firm’s AR is declining while MCHP shows 3.73%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-2.21%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-7.70%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-7.50%
We have a declining book value while MCHP shows 4.91%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-6.09%
Our R&D shrinks while MCHP invests at 1.80%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-1.63%
We cut SG&A while MCHP invests at 1.44%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.